Finance

Lists
DEVA:IST
Deva Holding AS
TRY 86,25
+0,29%
(+0,25) 1D
8 Okt., 14:27:48 GMT+3  ·   TRY
All symbols
SymbolPriceChange% Change
Generating top insights for DEVA...
Open
TRY 85,90
High
TRY 86,95
Low
TRY 85,40
Mkt. cap
17,66 mjd
Avg. vol.
707,22 k
Volume
88,60 k
52-wk high
TRY 109,30
52-wk low
TRY 57,50
EPS
-TRY 4,21
Shares outstanding
200,02 m
No. of employees
3 k
Open
TRY 85,90
High
TRY 86,95
Low
TRY 85,40
Mkt. cap
17,66 mjd
Avg. vol.
707,22 k
Volume
88,60 k
52-wk high
TRY 109,30
52-wk low
TRY 57,50
EPS
-TRY 4,21
Shares outstanding
200,02 m
No. of employees
3 k
News stories
From web sources and news partners
Profile
DEVA Holding A.Ş. is a Turkish pharmaceutical company operating since 1958. Its principal activities include the development, manufacture and marketing of human pharmaceuticals and active pharmaceutical ingredients. The company also operates in veterinary medicines, cologne, medical ampoules and food supplements. A majority stake in the company was acquired by EastPharma in 2006. DEVA Holding is listed on Borsa Istanbul, and its chairman and chief executive officer is Philipp Haas. As of 2025, the company had more than 675 products across 15 therapeutic areas. According to IQVIA data cited in its annual report, DEVA ranked third in the Turkish pharmaceutical market by unit sales in 2025, with a market share of 4.5%. Wikipedia
About Deva Holding AS
CEO-
Employees3,06 k
Founded22 Sep. 1958
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in TRY
Loading Previous Earnings...
Revenue
Net income
All values in TRY
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
4,47 mjd
5,49 mjd
6,33 mjd
6,00 mjd
Cost of goods sold
3,02 mjd
3,84 mjd
4,10 mjd
2,82 mjd
Cost of revenue
3,02 mjd
3,84 mjd
4,10 mjd
2,82 mjd
Research and development expenses
264,29 m
174,34 m
361,82 m
480,63 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,30 mjd
1,58 mjd
1,60 mjd
1,68 mjd
Operating expense
1,55 mjd
1,74 mjd
1,93 mjd
2,07 mjd
Total operating expenses
4,58 mjd
5,58 mjd
6,03 mjd
4,89 mjd
Operating income
-102,14 m
-89,10 m
293,59 m
1,11 mjd
Other non operating income
337,87 m
185,09 m
663,10 m
-172,42 m
EBT including unusual items
-137,34 m
-340,89 m
585,37 m
527,53 m
EBT excluding unusual items
-137,34 m
-362,51 m
586,40 m
527,53 m
Income tax expense
-116,52 m
1,00 mjd
682,64 m
-86,52 m
Effective tax rate
84,84%
-294,28%
116,62%
-16,40%
Other operating expenses
-9,80 m
-11,48 m
-34,86 m
-88,91 m
Net income
-20,81 m
-1,34 mjd
-97,27 m
614,05 m
Net profit margin
-0,47%
-24,48%
-1,54%
10,23%
Earnings per share
-
-
-
-
Interest and investment income
59,54 m
23,47 m
114,43 m
157,88 m
Interest expense
-617,63 m
-656,70 m
-542,37 m
-662,77 m
Net interest expenses
-558,09 m
-633,23 m
-427,95 m
-504,88 m
Depreciation and amortization charges
-
-
-
-
EBITDA
237,92 m
622,26 m
701,87 m
1,42 mjd
Gain or loss from assets sale
-15,06 m
-15,93 m
-32,28 m
-12,59 m
AI content may include mistakes. Learn more
Google-programme